Instil Bio Inc
NASDAQ:TIL
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
10.78
37.565
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Instil Bio Inc
Income from Continuing Operations
Instil Bio Inc
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
I
|
Instil Bio Inc
NASDAQ:TIL
|
Income from Continuing Operations
-$74m
|
CAGR 3-Years
22%
|
CAGR 5-Years
-63%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Income from Continuing Operations
$2.4B
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-2%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Income from Continuing Operations
$8.1B
|
CAGR 3-Years
35%
|
CAGR 5-Years
46%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Income from Continuing Operations
$7B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Income from Continuing Operations
$3.7B
|
CAGR 3-Years
4%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Income from Continuing Operations
$4.6B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
8%
|
CAGR 10-Years
23%
|
|
Instil Bio Inc
Glance View
Instil Bio, Inc. is a clinical-stage biopharmaceutical company engages in developing cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company is headquartered in Dallas, Texas and currently employs 412 full-time employees. The company went IPO on 2021-03-19. The firm is focused on developing a cell therapy pipeline of autologous tumor-infiltrating lymphocyte (TIL) therapies for the treatment of patients with cancer. TIL therapies leverage platform for TIL manufacturing has been designed for the scalability, logistics, and accessibility of TIL therapy. The company is advancing its lead TIL product candidate, ITIL-168, for the treatment of advanced melanoma. The company is also developing a class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR) platform. ITIL-168 is an autologous TIL therapy that it is initially developed for the treatment of PD-1-inhibitor relapsed or refractory advanced melanoma. Its pipeline also includes ITIL-306, its CoStAR-TIL product candidate.
See Also
What is Instil Bio Inc's Income from Continuing Operations?
Income from Continuing Operations
-74m
USD
Based on the financial report for Dec 31, 2024, Instil Bio Inc's Income from Continuing Operations amounts to -74m USD.
What is Instil Bio Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-63%
Over the last year, the Income from Continuing Operations growth was 53%. The average annual Income from Continuing Operations growth rates for Instil Bio Inc have been 22% over the past three years , -63% over the past five years .